Strategic Partnerships Seismic Therapeutic's ML-driven immunology discovery platform and growing preclinical pipeline, including an exclusive antibody license with Integral Molecular, positions the company as an attractive partner for pharma and biotech seeking accelerated discovery in autoimmune diseases.

Investor Validation Backing from high-profile life sciences investors and leadership appointments signal strong financial backing and a readiness to scale partnerships, licensing deals, and joint development programs.

Autoimmune Focus With a focus on dysregulated adaptive immunity and multiple autoimmune diseases, Seismic's IMPACT platform offers clear collaboration opportunities for co-development, licensing, or research services with pharma companies pursuing autoimmune programs.

Biotech Hub Advantage Based in the Boston ecosystem with access to top academic resources and a dense network of CROs and manufacturers, the company can leverage local partnerships, talent, and investor activity to accelerate deals.

Tech-Driven Discovery A cloud-based, data-driven approach using Python, Google Cloud, and other modern tools underpins rapid candidate generation and optimization, presenting opportunities to partner for computational biology services, data analytics, or platform-linked collaborations.